U.S., March 19 -- ClinicalTrials.gov registry received information related to the study (NCT06882317) titled 'Long Term Follow-up Study for Subjects Administered CLBR001' on March 12.
Brief Summary: The goal of this Long Term Follow-Up observational study is to monitor subjects who have received CLBR001, a lentiviral vector based chimeric antigen receptor, for delayed adverse events that may be associated with human gene therapies.
Participants will be followed for 15 years post-gene therapy administration date for safety and efficacy.
Study Start Date: May, 2025
Study Type: OBSERVATIONAL
Condition:
Long Term Follow-Up
Intervention:
OTHER: Long Term Follow-Up
No intervention is administered on this study. Subjects who have received...